Intervacc AB

IVACC · Nasdaq Stockholm · Healthcare

0.97SEK −5.7%last day

Price as of 2 October 2026

The price over the past year, with dividends: −6.6%

Performance

1 month

−14.4%

1 year

−6.6%

3 years, per year

−34.8%

5 years, per year

−55.5%

Largest fall, 3 years

−98.1%

Below the peak now

−98.7%

Volatility, 1 year

66.2%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

1.4

Dividend yield

0.0%

Return on equity

−39.4%

Net margin

−189.7%

Market value

33 m USD

Quality, value and trend

Where Intervacc stands against every Nordic stock today. 100 is best.

Quality73

Profitability and a sound balance sheet over time. Better than 73% of Nordic stocks.

Value16

The price measured against earnings, assets and cash flow. Better than 16% of Nordic stocks.

Trend45

The price development over the past year. Better than 45% of Nordic stocks.

Combined37

Quality, value and trend together. Better than 37% of Nordic stocks.

About Intervacc

Intervacc AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 16 employees.

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Strangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and sheep. The company was incorporated in 1983 and is based in Hägersten, Sweden.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis